BAC vs HRMY Stock Comparison
HRMY currently leads BAC in this stock comparison, with AIQ scores of 73 vs 58. The clearest difference is momentum, while BAC has the stronger risk resilience profile.
What is the main difference between BAC and HRMY?
HRMY leads the current stock comparison as Harmony Biosciences Holdings, Inc., with the clearest separation coming from momentum and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Bank of America Corporation vs Harmony Biosciences Holdings, Inc.
HRMY leads
HRMY leads by 15 AIQ points, primarily on Momentum and Value, but the lead has narrowed from 18 points over 30 sessions.
Stable: 4 of 6 evidence groups support HRMY, its lead is narrowing, and its signal state is cleanly positive.
Bank of America Corporation
Harmony Biosciences Holdings, Inc.
The Algovestiq AIQ Score currently favors HRMY over BAC, 73 versus 58 as of Nov 15, 2026. HRMY's advantage is driven primarily by stronger momentum and value, while BAC holds the stronger risk resilience profile. HRMY also shows the weaker technical structure relative to its 50-day moving average. 4 of 6 covered evidence groups favor HRMY today, and the comparison is rated Stable on stability: the leader's advantage has been narrowing. HRMY lead: Weakening — the AIQ differential moved from 18 to 15 points over 30 sessions.
Compare Bank of America Corporation and Harmony Biosciences Holdings, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Total return with distributions reinvested, from daily closes.
Total return comparison
Growth of $10,000, distributions reinvested
Split-adjusted closes; each distribution is reinvested at the close on its ex-dividend date. Taxes and trading costs are not modeled.
Compare BAC and HRMY against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Momentum37 vs 66HRMY +29
- Value68 vs 89HRMY +21
- Risk Resilience83 vs 63BAC +20
- Quality64 vs 77HRMY +13
4 of 6 evidence groups favor HRMY. HRMY’s edge is concentrated in momentum and value; BAC keeps a meaningful risk resilience edge.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
No factor moved materially.
New signals
- OBV Bullish Divergence — bullish, volume, medium horizon (-0.4%)
Largest factor move: Quality +1, not enough on its own to move the overall score.
No signal started or stopped since the prior session; its 3 active signals are unchanged.
HRMY's lead was unchanged in the latest session.
Deeper signal detail for each name lives on its own signals page — BAC and HRMY both carry a full feed there.
The central trade-off
HRMY (Harmony Biosciences Holdings, Inc.): the stronger current systematic profile, led by momentum and value.
BAC (Bank of America Corporation): the counter-case, on risk resilience, technicals.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
HRMYHRMY on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
BACBAC on combined revenue and EPS growth.
Value
HRMYHRMY on the peer-relative Value factor, by 21 points.
Momentum
HRMYHRMY on the Momentum factor, by 29 points.
Lower downside
BACBAC on Risk Resilience, by 20 points.
Analyst upside
HRMYHRMY on implied upside to the consensus price target.
AIQ vs Wall Street
Where the systematic read and the analyst consensus line up — and where they do not.
| Measure | BAC | HRMY | Note |
|---|---|---|---|
| Implied upside to target | +24.1% | +52.5% | HRMY has more room |
| Target dispersion | +25.3% | +35% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 25 | 12 | Higher coverage generally improves confidence |
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
4 of 6 covered evidence groups favor HRMY. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | HRMY | 58 vs 73 |
| Fundamentals | HRMYon balance | revenue growth -3.3% vs 2.9%; EPS growth -23.8% vs -36.2%; TTM ROE 2.3% vs 4.5%; gross margin 60.4% vs 74%; operating margin 22.4% vs 22.2% — HRMY takes 3 of 4 decided legs, not all of them |
| Valuation | HRMY | Value 68 vs 89 |
| Technicals | BAC | Price vs 50-day -5.6% vs -12.6%; vs 200-day -7% vs -2.4% |
| Risk Resilience | BAC | Risk Resilience 83 vs 63 |
| Analyst expectations | HRMY | Target upside 24.1% vs 52.5% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of BAC and HRMY and are excluded from the count.
AIQ Decision Stability
The conclusion rests on a wide gap and broad agreement. It is unlikely to turn on a single session.
- The AIQ gap is wide at 15 points. (supports the conclusion holding)
- The leader's advantage has been narrowing. (argues the conclusion is provisional)
- The lead has been steady session to session. (supports the conclusion holding)
- The leader's signal state is cleanly positive. (supports the conclusion holding)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on HRMY.
How the comparison changed
120 daily snapshots · May 27 – Nov 13HRMY lead: Weakening — the AIQ differential moved from 18 to 15 points over 30 sessions.
- Today
- HRMY +15
- 58 vs 73
- 7 sessions ago
- HRMY +18
- 58 vs 76
- 30 sessions ago
- HRMY +18
- 62 vs 80
- 90 sessions ago
- HRMY +3
- 71 vs 74
The lead has not changed hands in this window.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
2 bullish / 2 bearish / 1 neutral, conflicted
Only BAC
- Bollinger Band Squeeze — neutral, volatility, short horizon (4.5%)
- Death Cross Active — bearish, trend, long horizon (1.45%)
- Downtrend Structure Active — bearish, trend, long horizon
- MACD Histogram Expanding Bullish — bullish, momentum, short horizon
- OBV Bullish Divergence — bullish, volume, medium horizon (-0.4%)
1 bullish / 0 bearish / 2 neutral
Only HRMY
- Golden Cross Active — bullish, trend, long horizon (11.79%)
- ADX Trend Strengthening — neutral, trend, medium horizon
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (4.79%)
BAC is conflicted, so the timing case there is weaker than the score alone suggests.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price +1.01%, AIQ 0 points).
Neither the price nor the AIQ Score moved enough in the latest session to confirm or contradict the other (price -0.12%, AIQ 0 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1BAC closes the Momentum gap — currently 29 points behind, the largest single contributor to HRMY's edge.
- 2BAC's Death Cross Active resolves — a bearish trend rule currently active against it.
- 3HRMY's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict.
- 4The narrowing continues — the lead has already given back 3 points over 30 sessions, and a further 15-point move would eliminate HRMY's advantage entirely.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
HRMY leads on balance| Metric | BAC | HRMY |
|---|---|---|
| Revenue growth (YoY) | -3.3% | 2.9% |
| EPS growth (YoY) | -23.8% | -36.2% |
| Gross margin | 60.4% | 74% |
| Operating margin | 22.4% | 22.2% |
| Return on equity (TTM) | 2.3% | 4.5% |
| Debt to equity | 1.28 | 0.14 |
Performance
Split across windows| Metric | BAC | HRMY |
|---|---|---|
| 1 week (5 sessions) | 3.2% | 2% |
| 1 month (20 sessions) | -0.4% | -11% |
| 3 months (63 sessions) | -20.1% | -11.5% |
| 6 months (126 sessions) | 2.5% | 12.2% |
| Year to date | -7.2% | -9.8% |
| 1 year (252 sessions) | -5.7% | 0.7% |
Technicals
BAC has the stronger structure| Metric | BAC | HRMY |
|---|---|---|
| RSI (14) | 45.9 | 36.4 |
| ADX (14) | 27.2 | 34.7 |
| Price vs 50-day | -5.6% | -12.6% |
| Price vs 200-day | -7% | -2.4% |
| Volatility (1M, annualized) | 24.8% | 46.4% |
Risk
BAC is the more resilient| Metric | BAC | HRMY |
|---|---|---|
| Beta | 0.79 | 0.63 |
| Sharpe ratio | -0.22 | 0.07 |
| Sortino ratio | -0.29 | 0.09 |
| Max drawdown | -23.7% | -34.5% |
| Current drawdown | -21.3% | -21.2% |
| Annualized volatility | 22.4% | 40.6% |
| Value at risk (95%) | -2.6% | -3.9% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, BAC or HRMY?
On the Algovestiq AIQ Score, HRMY is the stronger of the two as of Nov 15, 2026, scoring 73 against BAC's 58. The edge comes from momentum and value. BAC is not without a case — it holds the better risk resilience profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is BAC or HRMY the better buy right now?
HRMY carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Stable — 4 of 6 covered evidence groups agree. A Stable rating means the gap is wide and the evidence is broad, so the conclusion is unlikely to turn on a single session.
Why does the AIQ Score favor HRMY over BAC?
The composite weights Quality, Value, Momentum and Risk Resilience. HRMY leads Momentum by 29 points; HRMY leads Value by 21 points; BAC leads Risk Resilience by 20 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, BAC or HRMY?
Analyst price targets imply +24.1% upside for BAC and +52.5% for HRMY, so the Street currently favors HRMY. The model and the Street agree here, which is a broader base of evidence than either alone. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, BAC or HRMY?
HRMY is the better-valued of the two on the peer-relative Value factor. HRMY on the peer-relative Value factor, by 21 points. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, BAC or HRMY?
BAC on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, BAC or HRMY?
HRMY on the Momentum factor, by 29 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, BAC or HRMY?
BAC is the more resilient of the two, so the other name carries the higher downside risk. BAC on Risk Resilience, by 20 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is BAC more profitable than HRMY?
HRMY leads on the comparable margin measures — gross margin 60.4% vs 74%; operating margin 22.4% vs 22.2%; ttm roe 2.3% vs 4.5%.
Is HRMY's lead over BAC getting stronger or weaker?
HRMY lead: Weakening — the AIQ differential moved from 18 to 15 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has not changed hands in that window.
What would change the BAC vs HRMY verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: BAC closes the Momentum gap — currently 29 points behind, the largest single contributor to HRMY's edge; BAC's Death Cross Active resolves — a bearish trend rule currently active against it; HRMY's Golden Cross Active breaks down — it is the strongest rule currently supporting the verdict; the narrowing continues — the lead has already given back 3 points over 30 sessions, and a further 15-point move would eliminate HRMY's advantage entirely.
What do the current signals say about BAC and HRMY?
BAC: 2 bullish / 2 bearish / 1 neutral, conflicted. HRMY: 1 bullish / 0 bearish / 2 neutral. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on BAC is Death Cross Active (bearish, long horizon). On HRMY it is Golden Cross Active (bullish, long horizon).
Compare BAC and HRMY with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.